GlassScriptPhysician profile
Anna Jean Keating
NPI 1194407916
$3,773.23
in general payments reported to CMS, 2019-2025
26 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $162 · 2024: $1,954 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $442.86 | 2023-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $345.86 | 2024-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $334.09 | 2023-2025 | Austedo Xr, Ajovy |
| Abbvie INC. | $331.06 | 2024-2025 | |
| Argenx US, INC. | $313.99 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $309.25 | 2023-2025 | |
| Ucb, INC. | $217.00 | 2025 | Rystiggo |
| Alexion Pharmaceuticals, INC. | $199.40 | 2023-2025 | Ultomiris, Soliris |
| Takeda Pharmaceuticals U.S.A., INC. | $139.06 | 2024-2025 | Hyqvia |
| Genentech USA, INC. | $138.12 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Tg Therapeutics, INC. | $133.30 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $128.96 | 2024-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Lilly USA, LLC | $128.56 | 2024-2025 | Kisunla, Amyvid |
| Neurocrine Biosciences, INC. | $84.16 | 2024-2025 | Ingrezza |
| Biogen, INC. | $74.41 | 2023-2025 | Leqembi, Aduhelm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $73.51 | 2024-2025 | Rexulti |
| Emd Serono, INC. | $58.47 | 2025 | |
| Pfizer INC. | $57.09 | 2024 | |
| Tanabe Pharma America, INC. | $47.10 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $46.64 | 2024 | Wainua |
| Harmony Biosciences LLC | $35.01 | 2025 | |
| Axsome Therapeutics, INC. | $33.13 | 2025 | Symbravo |
| Sk Life Science, INC. | $30.44 | 2025 | |
| Kyowa Kirin, INC. | $29.62 | 2023 | Nourianz |
| Novartis Pharmaceuticals Corporation | $22.13 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.01 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.